Dymicron, Inc., a privately held company in Orem, Utah, and maker of the Triadyme-C, recently announced the appointment of Ted Bird as Executive Vice President, Corporate Development and Chief Strategy Officer. Eric Lange also joins the company as Vice President, Regulatory Strategy.
Ted Bird and Eric Lange Join Dymicron Executive Team
1 min read Premium comments
Secondary#dymicron#ericlange#tedbird
Ted Bird brings 30 years of spine industry experience with roles in global marketing, medical education and business development at Medtronic Sofamor Danek. He was also vp of spine arthroplasty at DePuy Spine, president of the Spinal Implants Division of Orthofix, chief commercial officer at Titan Spine and non-executive chairman of the board at ApiFix. Additionally, he has provided strategic consulting through his own business venture, Bird Medical Group.
Eric Lange has been with Dymicron since May 2019 working toward U.S. approval of the Triadyme-C Cervical Disc. His 27 years of spine device experience include 20 years of product development leadership at Medtronic. He has over 100 patents and has been responsible for 29 worldwide product launches. Lange has also worked with Synthes Spine, Wright Medical and Smith & Nephew.
In a press release announcing the appointments, company Chairman and CEO Alan Layton said, “We are excited to have Ted and Eric join our leadership team. Their backgrounds, achievements, deep experience, and relationships in the spine industry will be invaluable in guiding the company as we transition from the development stage to FDA clinical trials in the U.S. and to commercialization in select countries outside the U.S.”
Triadyme-C is a cervical total disc replacement device that is unique in design and material. Between the titanium plasma sprayed titanium endplates is a polycrystalline diamond tri-lobed bearing. The composite material is as hard as natural diamond, resists brittle fracture, and has a low coefficient of friction for wear resistance over 1,000 times greater than cobalt-chrome. The tri-lobe design allows for a similar movement experience as a natural disc, such as increased energy requirements for movements near the limit of motion and self-centering. Triadyme-C is currently CE marked but awaiting U.S. approval.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.